292 related articles for article (PubMed ID: 33675094)
1. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
[TBL] [Abstract][Full Text] [Related]
3. PreS deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection.
Li X; Qin Y; Liu Y; Li F; Liao H; Lu S; Qiao Y; Xu D; Li J
J Clin Virol; 2016 Sep; 82():27-32. PubMed ID: 27415434
[TBL] [Abstract][Full Text] [Related]
4. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients.
Thi Cam Huong N; Trung NQ; Luong BA; Tram DB; Vu HA; Bui HH; Pham Thi Le H
PLoS One; 2022; 17(4):e0266134. PubMed ID: 35390033
[TBL] [Abstract][Full Text] [Related]
6. Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice.
Teng YC; Neo JC; Wu JC; Chen YF; Kao CH; Tsai TF
J Pathol; 2017 Mar; 241(4):463-474. PubMed ID: 27868197
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma and hepatitis B surface protein.
Li YW; Yang FC; Lu HQ; Zhang JS
World J Gastroenterol; 2016 Feb; 22(6):1943-52. PubMed ID: 26877602
[TBL] [Abstract][Full Text] [Related]
8. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma.
Yin J; Xie J; Zhang H; Shen Q; Han L; Lu W; Han Y; Li C; Ni W; Wang H; Cao G
J Gastroenterol; 2010 Oct; 45(10):1063-71. PubMed ID: 20419326
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk.
Wungu CDK; Ariyanto FC; Prabowo GI; Soetjipto S; Handajani R
J Viral Hepat; 2021 Jan; 28(1):61-71. PubMed ID: 32896077
[TBL] [Abstract][Full Text] [Related]
10. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.
Pollicino T; Amaddeo G; Restuccia A; Raffa G; Alibrandi A; Cutroneo G; Favaloro A; Maimone S; Squadrito G; Raimondo G
Hepatology; 2012 Aug; 56(2):434-43. PubMed ID: 22271491
[TBL] [Abstract][Full Text] [Related]
11. Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment.
Zhang D; Dong P; Zhang K; Deng L; Bach C; Chen W; Li F; Protzer U; Ding H; Zeng C
BMC Microbiol; 2012 Dec; 12():307. PubMed ID: 23272650
[TBL] [Abstract][Full Text] [Related]
12. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
13. Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma.
Gao ZY; Li T; Wang J; Du JM; Li YJ; Li J; Lu FM; Zhuang H
J Gastroenterol; 2007 Sep; 42(9):761-8. PubMed ID: 17876546
[TBL] [Abstract][Full Text] [Related]
14. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.
Liu S; Zhang H; Gu C; Yin J; He Y; Xie J; Cao G
J Natl Cancer Inst; 2009 Aug; 101(15):1066-82. PubMed ID: 19574418
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Hepatitis B Virus Mutations Leading to Endoplasmic Reticulum Stress and Their Contribution to the Progression of Hepatocellular Carcinoma.
Choi YM; Lee SY; Kim BJ
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704071
[TBL] [Abstract][Full Text] [Related]
16. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing.
Wang Y; Xiao X; Chen S; Huang C; Zhou J; Dai E; Li Y; Liu L; Huang X; Gao Z; Wu C; Fang M; Gao C
Front Immunol; 2021; 12():775461. PubMed ID: 34899733
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
[TBL] [Abstract][Full Text] [Related]
18. Association of novel mutations and haplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma.
Xie JX; Zhao J; Yin JH; Zhang Q; Pu R; Lu WY; Zhang HW; Wang HY; Cao GW
Front Med China; 2010 Dec; 4(4):419-29. PubMed ID: 21104161
[TBL] [Abstract][Full Text] [Related]
19. Occult infection with hepatitis B virus PreS variants synergistically promotes hepatocellular carcinoma development in a high-fat diet context by generating abnormal ceramides.
Liu C; Chen K; Zhao F; Xuan L; Wang Y; Xu C; Wu Z; Wang D; Qu C
BMC Med; 2022 Sep; 20(1):279. PubMed ID: 36058909
[TBL] [Abstract][Full Text] [Related]
20. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro.
Salpini R; Surdo M; Warner N; Cortese MF; Colledge D; Soppe S; Bellocchi MC; Armenia D; Carioti L; Continenza F; Di Carlo D; Saccomandi P; Mirabelli C; Pollicita M; Longo R; Romano S; Cappiello G; Spanò A; Trimoulet P; Fleury H; Vecchiet J; Iapadre N; Barlattani A; Bertoli A; Mari T; Pasquazzi C; Missale G; Sarrecchia C; Orecchini E; Michienzi A; Andreoni M; Francioso S; Angelico M; Verheyen J; Ceccherini-Silberstein F; Locarnini S; Perno CF; Svicher V
Oncotarget; 2017 Feb; 8(9):15704-15715. PubMed ID: 28152517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
